• Zolmitriptan: 5-HT1B Receptor Agonist Workflows in Migraine

  2026-05-29

  Zolmitriptan, a potent 5-HT1B receptor agonist, enables precise migraine and cluster headache research through validated, reproducible workflows. Explore advanced experimental protocols, real-world troubleshooting, and the translational advantages of APExBIO's high-purity Zolmitriptan.

• Acute Bright Light Triggers Prolonged Anxiety via ipRGC–CeA

  2026-05-29

  The referenced study reveals that brief exposure to bright light induces sustained anxiety-like behaviors in mice, mediated by a melanopsin-based retinal ganglion cell pathway projecting to the central amygdala. This work establishes a non-image forming visual circuit for delayed anxiety extinction, with implications for understanding light’s neuropsychiatric impacts.

• CP-673451 in ATRX-Deficient Glioma: PDGFR Inhibition Redefin

  2026-05-28

  Explore how CP-673451, a selective PDGFRα/β inhibitor, enables advanced cancer research by targeting ATRX-deficient glioma models. This article provides a detailed mechanistic analysis and practical assay insights beyond standard application guides.

• Fangchinoline Restores Lysosomal Biogenesis to Counter H1N1

  2026-05-28

  This study identifies fangchinoline as a lysosome-targeting compound that restores TFEB-driven lysosomal biogenesis, disrupting influenza A (H1N1) infection by counteracting viral strategies that impair lysosomal function. The findings underscore the therapeutic promise of modulating lysosomal pathways in antiviral research and open avenues for integrating lysosomal biology insights in related pharmacological studies.

• Biotin-tyramide: Precision Signal Amplification for IHC & IS

  2026-05-27

  Biotin-tyramide unlocks ultra-sensitive detection in immunohistochemistry and in situ hybridization by leveraging enzyme-mediated signal amplification. This guide details practical workflows, protocol parameters, and advanced troubleshooting to help researchers maximize specificity and signal strength in spatial biology assays.

• WAY-100635: Optimizing 5-HT1A Antagonism in Neuroscience Res

  2026-05-27

  WAY-100635 delivers unmatched selectivity for serotonin 5-HT1A antagonism, empowering researchers to dissect complex neuropharmacological circuits with confidence. This guide translates recent breakthroughs—especially those bridging serotonergic and cannabinoid pathways—into actionable workflows, troubleshooting strategies, and protocol enhancements for advanced neuroscience and behavioral pharmacology.

• Cefiderocol’s In Vitro Efficacy Against Resistant Enterobact

  2026-05-26

  Santerre Henriksen et al. present a pivotal analysis of cefiderocol’s in vitro activity against a broad cohort of European Enterobacterales, including isolates resistant to both meropenem and recently approved β-lactam/β-lactamase inhibitor combinations. The findings highlight cefiderocol’s superior or comparable efficacy, offering critical guidance for antimicrobial stewardship and future research on multidrug-resistant Gram-negative infections.

• WAY-100635: Unraveling 5-HT1A Antagonism in Pain and Emotion

  2026-05-26

  Explore HOW WAY-100635, a potent serotonin 5-HT1A antagonist, enables advanced neuroscience research on pain and emotion. This article goes beyond standard guides to dissect assay design, translational opportunities, and protocol refinements anchored in recent mechanistic findings.

• KR-12 Human Antimicrobial Peptide: Applied Research Workflow

  2026-05-25

  KR-12 (human) TFA is the minimal, potent fragment of LL-37, uniquely combining antimicrobial, anti-biofilm, and immunomodulatory properties with proven efficacy in preclinical models. This article details actionable protocols, troubleshooting strategies, and translational insights for deploying KR-12 in advanced infection, inflammation, and gut microbiome studies.

• Escitalopram in Translational Psychiatry: Mechanistic and St

  2026-05-25

  Explore the mechanistic precision and strategic value of Escitalopram (Lexapro) for translational neuroscience research. This article provides actionable guidance for leveraging high-purity Escitalopram from APExBIO in advanced antidepressant and anxiolytic models, integrating protocol advances, critical findings from augmentation trials, and a forward-looking perspective on serotonergic pathway research.

• Adefovir (GS-0393): Structural Selectivity and Advanced HBV

  2026-05-24

  Discover how Adefovir (GS-0393) achieves potent, selective inhibition of hepatitis B virus polymerase. This article offers a deep dive into the structural and mechanistic underpinnings that set Adefovir apart for advanced HBV research applications.

• High-Throughput BBB Model: Predicting CNS Drug Permeability

  2026-05-23

  The reference study introduces a robust, high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, enhancing the prediction of CNS drug permeability. By integrating lysosomal trapping correction, the model improves alignment with in vivo brain distribution, streamlining early-stage screening for brain-penetrant compounds.

• Thiothixene: Dual Antipsychotic and Efferocytosis Modulator

  2026-05-22

  Explore how Thiothixene, a typical antipsychotic agent, uniquely enhances macrophage efferocytosis in addition to its psychiatric applications. This article delves into breakthrough mechanistic insights and advanced assay guidance not covered in prior literature.

• Cisapride (R 51619): Deep Dive into Cardiotoxicity Modeling

  2026-05-22

  Explore how Cisapride (R 51619) advances cardiac electrophysiology research by enabling high-content, deep learning–driven detection of arrhythmia risk. This article uniquely links molecular pharmacology to next-generation phenotypic screening strategies.

• Placebo-Controlled Evidence for Mianserin HCl in Depression

  2026-05-21

  A rigorous double-blind, placebo-controlled trial established the antidepressant efficacy of Mianserin Hydrochloride in hospitalized women with severe depression. The study highlights significant improvements in both mood and sleep quality, supporting Mianserin HCl's role as a 5-HT2 receptor antagonist in psychiatric research.

15715 records 1/1048 page Next 12345 下5页 Last page